Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death.
about
A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myelomaTargeting interleukin-6 for noninfectious uveitisMonoclonal antibodies in the treatment of multiple myeloma: current status and future perspectivesNovel agents for multiple myeloma to overcome resistance in phase III clinical trialsDevelopment of Novel Immunotherapies for Multiple MyelomaSiltuximab (CNTO 328): a promising option for human malignanciesA phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma.New strategies in the treatment of multiple myeloma.Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma.Interleukin-6 in bone metastasis and cancer progression.A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.Antibody-based therapies in multiple myelomaTherapeutic monoclonal antibodies for multiple myeloma: an update and future perspectives.Process of hepatic metastasis from pancreatic cancer: biology with clinical significance.The development of potential antibody-based therapies for myelomaTrial Watch: Monoclonal antibodies in cancer therapyBlockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myelomaSynergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cellsTargeting PYK2 mediates microenvironment-specific cell death in multiple myeloma.Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications.Humoral immunotherapy of multiple myeloma: perspectives and perplexities.Monoclonal antibodies in the treatment of multiple myeloma.Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma.Molecular mechanisms of effectiveness of novel therapies in multiple myeloma.Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma.Experimental approaches in the treatment of multiple myeloma.Perspectives in the treatment of multiple myeloma.Monoclonal antibodies currently in Phase II and III trials for multiple myeloma.Siltuximab: first global approval.Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins.Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma.Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma.Emerging antibodies for the treatment of multiple myeloma.Sphingosine 1-phosphate signaling impacts lymphocyte migration, inflammation and infection.Association of promyelocytic leukemia protein with expression of IL-6 and resistance to treatment in multiple myeloma.Endothelial interleukin-6 defines the tumorigenic potential of primary human cancer stem cellsA phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation.
P2860
Q24646864-C8C77943-2056-478C-8B70-6A1598CCE0E1Q26782493-E4F41A20-A766-430F-AC84-437C665EFBB1Q26799104-721E01FD-5B18-4C0B-A5A1-E9842F5DB777Q26822754-DE131CF8-6DBA-4151-8160-D58A11086B9CQ28066890-3B999CFD-79CA-4BA4-9171-7424068B154CQ28082572-1D4FFF3F-8899-46D6-8617-6A2E2AD7982EQ33418036-24C3A89B-2C90-4349-BB15-C14B8239FA4EQ33420197-4C183391-0C4D-4138-832F-F111E263FEB0Q33958520-D966F063-BF75-4F2F-BD36-BBF2841B2257Q34009070-B23BAF6A-3BAB-4418-8D32-4F7DF5E450B2Q34051820-B5EC744D-07C5-4A60-9A44-F353BC4270E5Q34634446-D5AB94BF-ADAB-4F90-94F8-0AEB748C60B3Q35431150-3E290B2E-2CB5-453A-A9B4-0D121CB44612Q35514038-BDC9F2CD-0A80-470E-AD48-89C26C7DF96EQ35739397-43B098B4-C389-4F49-BF46-9A279CFBC0AEQ35788245-28D910FB-6AC2-4802-BF76-F07B167CA035Q36038408-480480B0-4758-4D9D-88D1-8655B7EA01A1Q36110746-75B58A5E-B7E9-4BFB-AC4B-59BF8EAA507DQ36121745-B34CBCD5-1F62-46D9-AC73-D6625E91432BQ36711842-64517D66-BA79-4205-93D3-AA010770D1B2Q37417591-B66BE43D-6057-4EE1-BA8E-6B9BF6083A42Q37724368-07BA305B-A45F-4961-BABF-FE0837F9CB40Q37903377-588F10B1-DCA2-440B-B472-096464D51966Q37919717-4A377E1F-FCEF-478F-A636-245BF4BD6913Q38035044-F70C389D-CB94-4BB4-BB2A-E9803F730E1FQ38090691-447244FE-6717-4F75-B393-012A00CDE71FQ38095958-7E1032D1-BDB4-45BD-8DE8-E6D9701A5782Q38108391-E1856149-0E5B-48E4-B659-5DB33BE55C76Q38205856-4C79C818-320B-46F4-8694-5F4AEF40ABC1Q38222680-AB433BC4-8B90-44A2-ACBA-2751A882BF0EQ38601582-B9E6A01F-8B50-4017-9321-D4EF6F45E893Q38679490-EE79E36E-F346-4C65-BF71-A1BBE3735CF7Q38737970-DD3AAD0B-439B-4A9F-BEBA-48201117C2A8Q38763837-3B5F8B3A-E57B-4FBB-8E43-418FAD23F833Q38838239-006F2719-6B71-40A1-A3C7-E75D6E6B26EAQ38880225-DF46E63F-C7AD-4A0F-A750-DFF15543C712Q39294366-90A1FC8A-B2E5-43C8-B280-79E245A8B4ACQ42548508-866CE9BC-1537-4276-AADC-BE7B27896074Q43761409-F1D13854-8740-4AF0-BC8B-E687214E0854Q43979784-B392D0D5-F446-43B7-8784-8DC6F66CA287
P2860
Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Targeted inhibition of interle ...... methasone-mediated cell death.
@ast
Targeted inhibition of interle ...... methasone-mediated cell death.
@en
Targeted inhibition of interle ...... methasone-mediated cell death.
@nl
type
label
Targeted inhibition of interle ...... methasone-mediated cell death.
@ast
Targeted inhibition of interle ...... methasone-mediated cell death.
@en
Targeted inhibition of interle ...... methasone-mediated cell death.
@nl
prefLabel
Targeted inhibition of interle ...... methasone-mediated cell death.
@ast
Targeted inhibition of interle ...... methasone-mediated cell death.
@en
Targeted inhibition of interle ...... methasone-mediated cell death.
@nl
P2093
P2860
P921
P1476
Targeted inhibition of interle ...... methasone-mediated cell death.
@en
P2093
Deborah J Kuhn
George W Small
Jeffrey A Nemeth
Peter M Voorhees
Sally A Hunsucker
P2860
P304
P356
10.1111/J.1365-2141.2009.07647.X
P407
P577
2008-03-06T00:00:00Z